Results 101 to 110 of about 14,520 (202)

Role of fulvestrant in the treatment of postmenopausal metastatic breast cancer patients

, 2016
Introduction: Endocrine therapy is considered the cornerstone treatment for postmenopausal women with hormone-receptor positive metastatic breast cancer.
Lambertini, Matteo, Lambertini M, Levaggi, Alessia, Del Mastro L, Vaglica M, Poggio, Francesca, Del Mastro, Lucia, Pronzato, Paolo, Poggio F, Blondeaux, Eva, Vaglica, Marina, Levaggi A   +11 more
core   +1 more source

Cediranib in Combination with Fulvestrant in Hormone-Sensitive Metastatic Breast Cancer: A Phase II Randomized Study.

, 2009
Background: Cediranib (RECENTIN™) is a highly potent VEGF signaling inhibitor that has shown clinical activity across a range of tumors at doses of 20, 30 and 45 mg, both as monotherapy and in combination with other agents.
J. Xu, J. Lombard, B. Mookerjee, A. Chan, J. Vinholes, C. de Oliveira, R. Snyder, D. Hyams, V. Alencar, M. Audeh, P. Klein   +10 more
core   +1 more source

Characterizing safety, toxicity, and breast cancer risk reduction using a long-term fulvestrant eluting implant

Scientific Reports
For individuals at high risk of developing breast cancer, interventions to mitigate this risk include surgical removal of their breasts and ovaries or five years treatment with the anti-estrogen tamoxifen or aromatase inhibitors.
Scott Thomas, Elysia Roche, Pujan Desai, Nela Pawlowska, Diana Bauer, David Gingrich, Emily Hsu, Amelia N. Deitchman, Fran Aweeka, Pamela N. Munster   +9 more
doaj   +1 more source

Case report: ex vivo tumor organoid drug testing identifies therapeutic options for stage IV ovarian carcinoma

Frontiers in Oncology
Patients presenting with stage 4 ovarian carcinoma, including low-grade serous disease, have a poor prognosis. Although platinum-based therapies can offer some response, these therapies are associated with many side effects, and treatment resistance ...
Marwah Al-Aloosi, Amanda M. Prechtl, Payel Chatterjee, Brady Bernard, Brady Bernard, Christopher J. Kemp, Rachele Rosati, Robert L. Diaz, Lauren R. Appleyard, Shalini Pereira, Alex Rajewski, Amber McDonald, Eva J. Gordon, Carla Grandori   +13 more
doaj   +1 more source

ISEV2026 Abstract Book

Journal of Extracellular Vesicles, Volume 15, Issue S1, June 2026.
wiley   +1 more source

Fulvestrant in the management of postmenopausal women with advanced, endocrine-responsive breast cancer

, 2011
Fulvestrant is a pure estrogen antagonist that binds, blocks and downgrades the estrogen receptor (ER). Its unique mechanism of action is its antitumor activity after progression on prior endocrine therapy. Fulvestrant has shown activity in ER-dependent
Catherine Oakman, Libero Santarpia, Erica Moretti, Angelo Di Leo   +3 more
core   +1 more source

ERβ is involved in fulvestrant-induced upregulation of hsa-miR-765 expression.

, 2014
(A) ERβ siRNA knockdown blocks fulvestrant-induced upregulation of hsa-miR-765 expression in DU145 cells. Expression levels of hsa-miR-765 determined by qRT-PCR analysis of the fulvestrant-treated cells with ERβ-siRNA (siERβ) or scramble negative-control
Queeny Kwan-Yi Chan (565317), Shuk-Mei Ho (128463), Yuet-Kin Leung (565316), Fanny Man-Ting Ma (565318), Kin-Mang Lau (565320), Ka-Fai To (109256), Jodi Maranchie (565319), Ho-Man Tse (331032), Chi-Fai Ng (3105801)   +8 more
core   +1 more source

Determination of Fulvestrant in Pharmaceutical Preparation by Square Wave and Differential Pulse Voltammetry Methods

, 2015
In this study, simple and fast square wave voltammetry (SWV) and differential pulse voltammetry (DPV) methods were developed and validated for determination of fulvestrant in pharmaceutical preparation.
ATİLA, Alptuğ, YILMAZ, Bilal
core  

Alpelisib (Kombination mit Fulvestrant)

Diese frühe Nutzenbewertung von Alpelisib (Piqray®) in Kombination mit Fulvestrant ist ein weiteres Verfahren zu einem neuen Arzneimittel beim metastasierten Mammakarzinom.
Bleckmann, Annalen, Wörmann, Bernhard, Deutsche Gesellschaft für Hämatologie und Medizinische Onkologie, Deutschland. Gemeinsamer Bundesausschuss   +3 more
core   +1 more source

Fulvestrant versus capecitabine as maintenance therapy in hormone receptor-positive, HER2-negative metastatic breast cancer after first-line chemotherapy (FAMILY): a multicenter, open-label, randomized, phase 3 trial. [PDF]

Signal Transduct Target Ther
Wu W, Yang Y, Chen H, Lu Y, Zeng Y, Zhao J, Du C, Lin Y, Peng P, Huang M, Zhang Y, Ouyang Q, Ding L, Cheng Z, Wen Y, Wu Z, Ye J, Ling L, Wang K, Lu Y, Zou G, Zhong J, Wang H, Lin D, Zeng, Yao C, Chen Q, Zou L, Wang S, Yu Y, Yuan Z, Wang Y, Yao H.   +32 more
europepmc   +1 more source